FDA Hematology and Oncology Approvals
Categories
FDA Hematology and Oncology Approvals
Explore new hematology and oncology treatments approved by the FDA. Learn about recent drug approvals for cancer and blood disorders.
Latest articles
37 articles
FDA Hematology and Oncology Approvals
FDA Approves Tucatinib for Maintenance Treatment of HER2-positive Metastatic Breast Cancer
FDA Hematology and Oncology Approvals
Pirtobrutinib (Jaypirca) Receives FDA Approval in Previously Untreated CLL
FDA Hematology and Oncology Approvals
Efsitora (Onswik) FDA Approval: The Second Once-Weekly Basal Insulin in Type 2 Diabetes
FDA Hematology and Oncology Approvals
FDA Approval of Belzutifan–Lenvatinib After Immunotherapy in Kidney Cancer
FDA Hematology and Oncology Approvals
Lirafugratinib FDA Approval: The Latest Stage of Targeted Treatment in Cholangiocarcinoma
FDA Hematology and Oncology Approvals
Ameluz Photodynamic Therapy: FDA Approval for Superficial Basal Cell Carcinoma
FDA Hematology and Oncology Approvals
Imlunestrant + Abemaciclib: New FDA Approval in ESR1-Mutated Breast Cancer
FDA Hematology and Oncology Approvals
Why the FDA Withdrew Approval of Adagrasib Plus Cetuximab in KRAS G12C Colorectal Cancer
FDA Hematology and Oncology Approvals
The First Drug Against Muscle Loss in Spinal Muscular Atrophy (SMA): Apitegromab Receives FDA Approval
FDA Hematology and Oncology Approvals
First-Line FDA Approval for Sevabertinib: HER2-Mutant Lung Cancer
FDA Hematology and Oncology Approvals